Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS: Interactions between C-C chemokine receptor types 2 (CCR2) and 5 (CCR5) and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation. Cenicriviroc (CVC) is an oral, dual CCR2/CCR5 antagonist with nanomolar potency against both receptors. CVC's anti-inflammatory and antifibrotic effects were evaluated in a range of preclinical models of inflammation and fibrosis. METHODS: Monocyte/macrophage recruitment was assessed in vivo in a mouse model of thioglycollate-induced peritonitis. CCL2-induced chemotaxis was evaluated ex vivo on mouse monocytes. CVC's antifibrotic effects were evaluated in a thioacetamide-induced rat model of liver fibrosis and mouse models of diet-induced non-alcoholic steatohepatitis (NASH) and renal fibrosis. Study assessments included body and liver/kidney weight, liver function test, liver/kidney morphology and collagen deposition, fibrogenic gene and protein expression, and pharmacokinetic analyses. RESULTS: CVC significantly reduced monocyte/macrophage recruitment in vivo at doses ≥20 mg/kg/day (p < 0.05). At these doses, CVC showed antifibrotic effects, with significant reductions in collagen deposition (p < 0.05), and collagen type 1 protein and mRNA expression across the three animal models of fibrosis. In the NASH model, CVC significantly reduced the non-alcoholic fatty liver disease activity score (p < 0.05 vs. controls). CVC treatment had no notable effect on body or liver/kidney weight. CONCLUSIONS: CVC displayed potent anti-inflammatory and antifibrotic activity in a range of animal fibrosis models, supporting human testing for fibrotic diseases. Further experimental studies are needed to clarify the underlying mechanisms of CVC's antifibrotic effects. A Phase 2b study in adults with NASH and liver fibrosis is fully enrolled (CENTAUR Study 652-2-203; NCT02217475).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 CVC Effect on Monocyte/Macrophage Migration. (A) Monocyte/macrophage recruitment reduced in TG-induced mouse model of peritonitis after pre-treatment with CVC (PO BID or QD dosing); (B) cenicriviroc (1 μM) inhibits CCL2-mediated chemotaxis of activated murine macrophages (F4/80+/CD11b+) ex vivo. *p < 0.05 vs. TG + vehicle control; **p < 0.01 vs. TG + vehicle control; ***p < 0.001 vs. TG + vehicle control; † p < 0.001 vs. TG + DEX; ‡ p = 0.018 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). BID, twice daily; CCL2, C-C chemokine ligand 2; CVC, cenicriviroc; CVC5, CVC 5 mg/kg/day; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; DEX, dexamethasone; PO, oral gavage; QD, once daily; SEM, standard error of the mean; TG, thioglycollate.](https://figures.cochat.ai/paper-figures/dfdd355eafec4c6e9c04f1a46b1d736c/antifibrotic-effects-of-the-dual-ccr2-ccr5-antagonist-cenicriviroc-in-animal-figure-1.jpg)
![Fig 2 Reduction of Plasma ALT Levels in NASH Model. *p < 0.05 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). ALT, alanine aminotransferase; BID, twice daily; CVC, cenicriviroc; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; NASH, non-alcoholic steatohepatitis; SD, standard deviation.](https://figures.cochat.ai/paper-figures/1a6e539bef254c4eae8e1034fb2ebd96/antifibrotic-effects-of-the-dual-ccr2-ccr5-antagonist-cenicriviroc-in-animal-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These preclinical studies demonstrated a significant reduction in collagen deposition (148).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [148]
In the citing paper
“Pharmacological inhibition of CCL2 by mNOX-E36 (121) or the use of cenicriviroc, a CCR2/CCR5 antagonist, gave promising anti-inflammatory and antifibrogenic results in mouse models (122).”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · doi:10.1146/annurev-pharmtox-020524-012013 · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“The NAS, a histological tool developed to assess disease severity in humans, was assessed in a blinded fashion and calculated according to Kleiner’s criteria on H&E-stained sections [38].”
MethodChronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383 · cited 1×
“Likewise, renal fibrosis is a common manifestation of chronic kidney disease [3], associated with elevated risks of morbidity and mortality [4].”
BackgroundPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“transforming growth factor-beta [TGF-beta]), produced by activated macrophages, promote transdifferentiation of HSCs into myofibroblasts, which are the primary source of scarforming matrix proteins, including fibrillary collagen types 1 and 3, and the contractile protein alpha-smooth muscle actin (alpha-SMA) [1,6–8].”
BackgroundRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894 · cited 2×
“Fibrosis results from a sustained inflammatory response to chronic organ injury and is characterized by the deposition of extracellular matrix proteins, including collagen types 1 and 3 [1].”
BackgroundSelf-citationRoles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829 · cited 1×
“CCR2 and CCR5 have become attractive targets for antifibrotic therapy, as interactions with their ligands, including CCL2 and CCL5, mediate recruitment of inflammatory cells to the site of liver injury, and contribute to fibrosis [9–15,40].”
BackgroundPradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613 · cited 1×
“transforming growth factor-beta [TGF-beta]), produced by activated macrophages, promote transdifferentiation of HSCs into myofibroblasts, which are the primary source of scarforming matrix proteins, including fibrillary collagen types 1 and 3, and the contractile protein alpha-smooth muscle actin (alpha-SMA) [1,6–8].”
Background
Research works printed but not linked: 3
- Jalbert E, Byron MM, Shikuma C, Jenkins H, Lefebvre E, Barbour JD. Cenicriviroc achieves high CCR5 receptor occupancy at low nanomolar concentrations. Presented at: 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); 2014 Mar 3; Boston, MA, USA. 530.
- MM Byron, 2015, Dual CCR2/CCR5 antagonism by cenicriviroc efficiently inhibits both MCP-1 and RANTES induced chemokine receptor internalization in murine pro-inflammatory monocytes, J Immunol, 194, 187, 10.4049/jimmunol.194.Supp.187.8 · DOI
- M Thompson, 2014, Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1 infected adults receiving cenicriviroc over 48 weeks, Hepatology, 60, 424A
Cited by
Items 101–200 of 326
Epigenetic Regulation of Kupffer Cell Function in Health and Disease
Bennett, H., Troutman, T. D., Sakai, M., & Glass, C. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609618 · Cited by 66
“Cenicriviroc, a CCR2/CCR5 antagonist, is in phase III clinical trials for the treatment of fibrosis in NASH (73).”
BackgroundRoles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis
Wang, M., Li, L., Xu, Y., Du, J., & Ling, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958428 · Cited by 69
“, 2016), and thus the dual CCR2/CCR5 inhibitor CVC can reduce fibrosis progression to some extent, which was evident in animal models (Lefebvre et al., 2016).”
BackgroundD’Antoni, M. L., Paul, R. H., Mitchell, B. I., Kohorn, L. B., Fischer, L., Lefebvre, E. A., Seyedkazemi, S., Nakamoto, B. K., Walker, M., Kallianpur, K. J., et al. (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001752 · Cited by 60
Self-citationKiapidou, S., Liava, C., Kalogirou, M., Akriviadis, E. A., & Sinakos, E. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2019.07.013 · Cited by 60
Segal-Salto, M., Barashi, N., Katav, A., Edelshtein, V., Aharon, A., Hashmueli, S., George, J., Maor, Y., Pinzani, M., Haberman, D., et al. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2019.100064 · Cited by 53
“Similar to previous publications, we found that livers from rats treatedwith TAA for 8 weeks exhibit extensive fibrosis visible upon gross examination, marked elevations of liver enzymes and elevated collagen content.(35) The CM-101-treated group exhibited a dramatic decrease in liver fibrosis compared to the vehicle-…”
BackgroundResultSelf-citationFuture trends in the treatment of non-alcoholic steatohepatitis
Fiorucci, S., Biagioli, M., & Distrutti, E. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.014 · Cited by 56
“3 and 4) is an antifibrotic agents that was shown effective in attenuating liver and kidney fibrosis in rodents [72].”
BackgroundNonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kim, K., Lee, B., Kim, Y. J., Lee, D. H., Soo, B., & Park, C. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0034 · Cited by 58
Human-based systems: Mechanistic NASH modelling just around the corner?
Boeckmans, J., Natale, A., Buyl, K., Rogiers, V., Kock, J. D., Vanhaecke, T., & Rodrigues, R. M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.029 · Cited by 56
Macrophages as key regulators of liver health and disease
Papachristoforou, E., & Ramachandran, P. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.006 · Cited by 70
Macrophages protect against sensory axon loss in peripheral neuropathy
Hakim, S., Jain, A., Adamson, S. S., Petrova, V., Indajang, J., Kim, H. W., Kawaguchi, R., Wang, Q., Duran, E. S., Nelson, D., et al. (2025) · Nature · doi:10.1038/s41586-024-08535-1 · Cited by 68
“Heat sensitivity assessed using Hargreaves assay in mice fed a CD for 12 weeks and injected with CVC or Veh starting after 8 weeks on diet.”
InfluentialImproving homing in T cell therapy
Vignali, D., & Kallikourdis, M. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.009 · Cited by 54
Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
Eshraghian, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i42.7495 · Cited by 53
Rotoli, B. M., Barilli, A., Visigalli, R., Ingoglia, F., Milioli, M., Lascia, M. D., Riccardi, B., Puccini, P., & Dall’Asta, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00508 · Cited by 57
Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study
Eksteen, B., Bowlus, C. L., Montaño‐Loza, A. J., Lefebvre, E. A., Fischer, L., Vig, P., Martins, E. B., Ahmad, J., Yimam, K. K., Pockros, P. J., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1619 · Cited by 60
“(19) CVC has demonstrated anti-inflammatory and antifibrotic activity across multiple animal models of liver disease.(19-23) Preclinical studies, including a rat bile duct ligation model of cholestasis, demonstrated that CVC (in combination with all-trans retinoic acid) was associated with reduced liver necrosis, hepa…”
BackgroundSelf-citationCurrent and future pharmacologic treatment of nonalcoholic steatohepatitis
Banini, B. A., & Sanyal, A. J. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000356 · Cited by 61
Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH)
Li, X., Ding, K., Li, X., Yuan, B., Wang, Y., Yao, Z., Wang, S.-K., Huang, H., Xu, B., Xie, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32163-w · Cited by 54
Jee, Y.-M., Lee, J., & Ryu, T. (2025) · Biomedicines · doi:10.3390/biomedicines13051260 · Cited by 70
“Cenicriviroc, a dual CCR2/CCR5 antagonist, demonstrated anti-fibrotic effects in the CENTAUR trial, although its phase III results (AURORA) were inconclusive [119,120].”
How to Face Chronic Liver Disease: The Sinusoidal Perspective
Fernández‐Iglesias, A., & Gracia‐Sancho, J. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00007 · Cited by 62
“It has been reported in preclinical models of fibrosis that inhibition of CCL2, or its receptor CCR2, promotes marked reduction in hepatic fibrosis (73).”
BackgroundImmune Cell Trafficking to the Liver
Chaudhry, S., Emond, J., & Griesemer, A. (2019) · Transplantation · doi:10.1097/tp.0000000000002690 · Cited by 38
“Dual inhibition of CCR2 and CCR5 reduces recruitment of monocytes and macrophages, as well as HSC activation in rodent liver fibrosis, significantly reducing fibrosis and inflammation.(246) CXCR1 and CXCR2 antagonism also dramatically inhibits myeloid recruitment in a I/R rat model of transplantation, leading to decre…”
BackgroundAdvances of CCR5 antagonists: From small molecules to macromolecules
Qi, B., Fang, Q., Liu, S., Hou, W., Li, J., Huang, Y., & Shi, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112819 · Cited by 56
The therapeutic landscape of non‐alcoholic steatohepatitis
Perazzo, H., & Dufour, J. (2016) · Liver International · doi:10.1111/liv.13270 · Cited by 52
Lefere, S., Devisscher, L., & Tacke, F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1718106 · Cited by 47
Ha, Y., Jeong, I., & Kim, T. H. (2022) · Biomedicines · doi:10.3390/biomedicines10102530 · Cited by 57
Albhaisi, S. A. M., & Sanyal, A. J. (2021) · Liver International · doi:10.1111/liv.14844 · Cited by 53
Animal models of portal hypertension
Königshofer, P., Brusilovskaya, K., Schwabl, P., & Reiberger, T. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.07.018 · Cited by 47
Ganguli, S., Deleeuw, P., & Satapathy, S. K. (2019) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s188991 · Cited by 49
Mohammed, O. S., Attia, H. G., Mohamed, B. M. S. A., Elbaset, M. A., & Fayed, H. M. (2023) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2023.11808 · Cited by 54
The Gut–Liver Axis in Chronic Liver Disease: A Macrophage Perspective
Muynck, K. D., Vanderborght, B., Vlierberghe, H. V., & Devisscher, L. (2021) · Cells · doi:10.3390/cells10112959 · Cited by 53
Bartneck, M., Koppe, C., Fech, V., Warzecha, K. T., Kohlhepp, M., Huss, S., Weiskirchen, R., Trautwein, C., Luedde, T., & Tacke, F. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.08.012 · Cited by 44
Yu, D., Cai, S., Mennone, A., Vig, P., & Boyer, J. L. (2018) · Liver International · doi:10.1111/liv.13698 · Cited by 45
BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate
Cherney, R. J., Anjanappa, P., Selvakumar, K., Batt, D. G., Brown, G. D., Rose, A., Vuppugalla, R., Chen, J., Pang, J., Xu, S., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00373 · Cited by 44
Alkhouri, N., & Scott, A. L. (2018) · Clinical Liver Disease · doi:10.1002/cld.708 · Cited by 41
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
The Potential Application of Magnetic Nanoparticles for Liver Fibrosis Theranostics
Eftekhari, A., Arjmand, A., Asheghvatan, A., Švajdlenková, H., Šauša, O., Abiyev, H., Ahmadian, E., Smutok, O. V., Khalilov, R. I., Kavetskyy, T. S., et al. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.674786 · Cited by 44
“The anti-fibrotic function of CVC was observed in vivo (Lefebvre et al., 2016).”
BackgroundCryo-electron microscopy for GPCR research and drug discovery in endocrinology and metabolism
Duan, J., He, X., Li, S., & Xu, H. E. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00957-1 · Cited by 47
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients
Ruberti, S., Bianchi, E., Guglielmelli, P., Rontauroli, S., Barbieri, G., Tavernari, L., Fanelli, T., Norfo, R., Pennucci, V., Fattori, G. C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.220 · Cited by 37
Musso, G., Michieli, F. D., Bongiovanni, D., Parente, R., Framarin, L., Leone, N., Berrutti, M., Gambino, R., Cassader, M., Cohney, S. J., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.08.002 · Cited by 38
Antifibrotics in liver disease: are we getting closer to clinical use?
Bansal, M. B., & Chamroonkul, N. (2018) · Hepatology International · doi:10.1007/s12072-018-9897-3 · Cited by 45
Emerging synthetic drugs for the treatment of liver cirrhosis
Fallowfield, J. A., Ramos, M. J., & Robertson, A. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1918099 · Cited by 41
“monocyte/macrophage accumulation in the liver and ameliorated fibrosis [73].”
BackgroundTreatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Golabi, P., Bush, H., & Younossi, Z. M. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.06.010 · Cited by 38
Functional roles of CCL5/RANTES in liver disease
Chen, L., Zhang, Q., Yu, C. J., Wang, F., & Kong, X. (2020) · Liver Research · doi:10.1016/j.livres.2020.01.002 · Cited by 40
The versatility of macrophage heterogeneity in liver fibrosis
Gao, C.-C., Bai, J., Han, H., & Qin, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968879 · Cited by 45
“Moreover, Cenicriviroc trial has excellent safety profile tested by clinical trials, suggesting that inhibition of monocyte recruitment will not affect the antimicrobial defense and immune responses of hepatic macrophages (92, 93).”
BackgroundCurrent Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041778 · Cited by 48
“…the efficacy of this approach by simultaneously reducing pro-inflammatory monocyte/macrophage activity and HSC-mediated fibrogenesis [171,172], as evidenced by clinical trials such as the CENTAUR phase 2b trial (NCT02217475), which demonstrated significant improvements in liver fibrosis…”
Macrophages and the development and progression of non-alcoholic fatty liver disease
Alabdulaali, B., Al‐Rashed, F., Al‐Onaizi, M., Kandari, A., Razafiarison, J., Tonui, D., Williams, M. R., Blériot, C., Ahmad, R., & Alzaïd, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1195699 · Cited by 39
“Cenicriviroc acts by decreasing recruitment of pro-inflammatory macrophages in mice with liver fibrosis (187).”
BackgroundTargeting tumor associated macrophages in hepatocellular carcinoma
Xu, W., Cheng, Y., Guo, Y., Yao, W., & He, Q. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114990 · Cited by 41
Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
Fu, Y., Zhou, Y., Shen, L., Li, X., Zhang, H., Cui, Y., Zhang, K., Li, W., Chen, W., Zhao, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.973366 · Cited by 40
“C chemokine receptor types 2 (CCR2) and 5 (CCR5) mediate fibrosis by recruiting inflammatory monocytes and macrophages and activating lymphocytes and hepatic stellate cells (Lefebvre et al., 2016; Tacke, 2018).”
BackgroundZaid, A. K. M. A., & Ariel, A. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115204 · Cited by 36
Liver fibrosis: pathological features, clinical treatment and application of therapeutic nanoagents
Chen, L., Guo, W., Mao, C., Shen, J., & Wan, M. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02790b · Cited by 38
Magnetic-Assisted Treatment of Liver Fibrosis
Levada, K. V., Omelyanchik, A. S., Rodionova, V. V., Weiskirchen, R., & Bartneck, M. (2019) · Cells · doi:10.3390/cells8101279 · Cited by 34
Biagioli, M., & Fiorucci, S. (2021) · Liver Research · doi:10.1016/j.livres.2021.08.003 · Cited by 37
Chen, J., Yao, Y., Su, X., Shi, Y., Song, X., Xie, L., You, J., Tian, L., Yang, L., Fang, A., et al. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3587 · Cited by 34
“To verify further the results from RNA‐Seq and RT‐PCR, immunohistochemical analysis was conducted to examine the in situ protein expressions of Ccl2 and Ccr2, which are two target genes for fibrosis treatment (Lefebvre et al., 2016).”
MethodNanoparticles retard immune cells recruitment in vivo by inhibiting chemokine expression
Xu, J., Wang, J., Qiu, J., Liu, H., Wang, Y., Cui, Y., Humphry, R., Wang, N., Durkan, C., Chen, Y., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120392 · Cited by 32
Bonnard, B., Ibarrola, J., Lima-Posada, I., Fernández-Celis, A., Durand, M., Genty, M., Lopez-Andreés, N., & Jaisser, F. (2021) · HYPERTENSION · doi:10.1161/hypertensionaha.121.17712 · Cited by 28
Therapeutic modulation of the liver immune microenvironment
Tilg, H., Adolph, T. E., & Tacke, F. (2023) · Hepatology · doi:10.1097/hep.0000000000000386 · Cited by 35
“193] In a phase 2b clinical trial involving patients with NASH and fibrosis, the initial fibrosis improvement after 1 year of treatment was not sustained after 2 years of therapy.”
BackgroundNASH: A glance at the landscape of pharmacological treatment.
Brodosi, L., Marchignoli, F., Petroni, M. L., & Marchesini, G. (2016) · PubMed · doi:10.5604/16652681.1212318 · Cited by 38
Chen, X., Wang, Z., Han, S., Wang, Z., Zhang, Y., Li, X., Xia, N. L., Yu, W., Jia, C., Ni, Y., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04403-2 · Cited by 34
“Cenicriviroc is a dual antagonist of CCR2 and CCR5, It has been proven to alleviate liver fibrosis in mice [25], and its anti-fibrotic effect has been demonstrated in the clinical data of phase IIb [26].”
BackgroundUnderstanding the Potential Role of Nanotechnology in Liver Fibrosis: A Paradigm in Therapeutics
Singh, S., Sharma, N., Shukla, S., Behl, T., Gupta, S., Anwer, M. K., Vargas-De-La-Cruz, C. B., BUNGAU, S. G., & Brisc, M. C. (2023) · Molecules · doi:10.3390/molecules28062811 · Cited by 36
“In numerous preclinical models of hepatic fibrosis, cenicriviroc, an oral antagonist in both chemokine receptor type 2 and type 5-dependent pathways, reduces the inflammatory response and fibrogenesis [83,84].”
BackgroundMcCullough, R. L., McMullen, M. R., Poulsen, K. L., Kim, A., Medof, M. E., & Nagy, L. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02133 · Cited by 30
“Since CCR2 and CCR5 contribute to hepatic inflammation and fibrosis (56, 57), the abundance of CCR2/5 ligands in both soluble and EV compartments should be assessed when considering the use of CCR2/5 antagonists for chronic liver diseases.”
BackgroundNonalcoholic Fatty Liver Disease in Children: Not a Small Matter
Selvakumar, P. K. C., Kabbany, M. N., & Alkhouri, N. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0292-2 · Cited by 33
“In animal models, cenicriviroc significantly decreased monocyte/macrophage recruitment and had an antifibrotic effect with decreased collagen deposition in the liver [117].”
BackgroundMacrophages as Key Players during Adipose Tissue–Liver Crosstalk in Nonalcoholic Fatty Liver Disease
Korf, H., Boesch, M., Meelberghs, L., & der Merwe, V. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1687851 · Cited by 30
New drugs for non‐alcoholic steatohepatitis
Cardoso, A. C., de Figueiredo-Mendes, C., Villela‐Nogueira, C. A., & Sanyal, A. J. (2020) · Liver International · doi:10.1111/liv.14354 · Cited by 31
Crucial role of T cells in NAFLD-related disease: A review and prospect
Mao, T., Yang, R. X., Luo, Y., & He, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1051076 · Cited by 33
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
Jeong, S. W. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0115 · Cited by 30
“Parallel CCR5 inhibition impairs the migration, activation and proliferation of activated hepatic stellate cells [76,77].”
BackgroundFisher, B. S., Green, R. R., Brown, R., Wood, M. P., Hensley‐McBain, T., Fisher, C., Chang, J., Miller, A. D., Bosche, W. J., Lifson, J. D., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006871 · Cited by 29
Oniciu, D. C., Hashiguchi, T., Shibazaki, Y., & Bisgaier, C. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194568 · Cited by 28
“Interactions between C-C chemokine receptor types 2 (CCR2) and its ligand, CCL2, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation [30].”
BackgroundMethodInfluentialSelf-citationCurrent Prevention and Treatment Options for NAFLD
Wong, V. W. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_12 · Cited by 31
Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease
Patel, S. S., & Siddiqui, M. S. (2018) · Drugs · doi:10.1007/s40265-018-1040-1 · Cited by 29
Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD
Dibba, P., Li, A. A., Perumpail, B. J., John, N., Sallam, S., Shah, N. D., Kwong, W., Cholankeril, G. T., Kim, D., & Ahmed, A. (2018) · Diseases · doi:10.3390/diseases6030083 · Cited by 31
“CVC demonstrated reduction in collagen deposition, collagen type 1 proteins, and mRNA in fibrosis [33].”
BackgroundMethodInfluentialSherman, K. E., Abdel-hameed, E. A., Rouster, S. D., Shata, M. T. M., Blackard, J. T., Safaie, P., Kroner, B. L., Preiss, L., Horn, P. S., & Kottilil, S. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy807 · Cited by 25
“Animal studies with CVC also support the concept that hepatic fibrosis is reduced following NASH or other injury [51, 52].”
BackgroundCurrent and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment
Chen, M., Cai, J., Yu, Y., She, Z., & Li, H. (2019) · Gene Expression · doi:10.3727/105221619x15536120524171 · Cited by 27
Liang, F., Giordano, C., Shang, D., Li, Q., & Petrof, B. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194421 · Cited by 29
Barbara, M., Scott, A. L., & Alkhouri, N. (2018) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2018.08.05 · Cited by 29
AlAsfoor, S., Rohm, T. V., Bosch, A. J. T., Dervos, T., Calabrese, D., Matter, M. S., Weber, A., & Cavelti‐Weder, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-32853-w · Cited by 29
Rothweiler, S., Feldbrügge, L., Jiang, Z. G., Csizmadia, E., Longhi, M. S., Vaid, K. A., Enjyoji, K., Popov, Y. V., & Robson, S. C. (2019) · Purinergic Signalling · doi:10.1007/s11302-019-09664-3 · Cited by 24
Pennisi, G., Celsa, C., Spatola, F., Dallio, M., Federico, A., & Petta, S. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16224334 · Cited by 33
“Several studies [126–128] support the anti-inflammatory and antifibrotic properties belonging to CVC in animal models of liver and kidney fibrosis [125,129].”
BackgroundCurrent strategies for nonalcoholic fatty liver disease treatment (Review)
Sun, J., Jin, X., & Li, Y. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5412 · Cited by 29
“…c motif chemokine receptor 2 (ccR2) reduced the accumulation, migration and infiltration of monocytes and macrophages to the liver, which decreased hepatic damage (215). ccR5 participates in acti‑ vation of hepatic stellate cells following liver injury, further aggravating hepatic fibrosis (216).”
BackgroundVonghia, L., Herck, M. A. V., Weyler, J., & Francque, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00563 · Cited by 25
“These findings are consistent with previous studies including those conducted in HIV patients (74, 77, 78).”
ResultMicrobiome-liver crosstalk: A multihit therapeutic target for liver disease
Kirundi, J., Moghadamrad, S., & Urbaniak, C. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i11.1651 · Cited by 26
“…such as C-C motif chemochine receptor (CCR) 2 and CCR5 [Cenicrivinoc (CVC)] have been used with some success to decrease leukocyte infiltration, and when used in a diet-induced NASH mouse model and a thioacetamide-induced fibrosis rat model, liver fibrosis was effectively reduced[115,116].”
D’Antoni, M. L., Mitchell, B. I., McCurdy, S., Byron, M. M., Ogata-Arakaki, D., Chow, D. C., Mehta, N. N., Boisvert, W. A., Lefebvre, E. A., Shikuma, C. M., et al. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5a0817-328rrr · Cited by 24
Self-citationKimura, T., Singh, S. B., Tanaka, N., & Umemura, T. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.773432 · Cited by 27
Kado, A., Tsutsumi, T., Enooku, K., Fujinaga, H., Ikeuchi, K., Okushin, K., Moriya, K., Yotsuyanagi, H., & Koike, K. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01565-x · Cited by 23
Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
Yu, S., Wang, J., Zheng, H., Wang, R., Johnson, N. L., Li, T., Li, P., Lin, J., Li, Y., Jin, Y., et al. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s377768 · Cited by 29
“Infiltration of neutrophils is among the main characteristics of NASH and contributes to its progression through the production of cytokines, ROS, and neutrophil extracellular traps (NETs).100,101 It has been shown that mice deficient of neutrophils or neutrophil effector molecules, such as proteases, elastase, and my…”
BackgroundInfluentialChen, J. Y. S., Chua, D., Lim, C. O., Ho, W. X., & Tan, N. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010158 · Cited by 27
Zuo, Q., Park, N. H., Lee, J. K., Casiano, A. S., & Madak‐Erdogan, Z. (2023) · Steroids · doi:10.1016/j.steroids.2023.109330 · Cited by 25
Clinical Trial Design for Alcoholic Hepatitis
Szabó, G. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1608788 · Cited by 25
Tsuchida, T. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.154.203 · Cited by 23
Diaz-Soto, M. P., & Lim, J. K. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s230613 · Cited by 25
Fiorucci, S., Urbani, G., Giorgio, C. D., Biagioli, M., & Distrutti, E. (2024) · Cells · doi:10.3390/cells13191650 · Cited by 26
“Cenicriviroc [155], a dual antagonist of CCR2 and CCR5 anti-fibrotic, was originally tested in an open-label, single-arm study for its efficacy in reducing ALP in PSC patients with minimal efficacy [156].”
MethodFuchs, C. D., SRODA, N., Scharnagl, H., Gupta, R. S., Minto, W. C., Stojaković, T., Liles, J. T., Budas, G. R., Hollenback, D., & Trauner, M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100874 · Cited by 24
“Hydroxyproline was measured biochemically and normalized to liver weight using cryo-powdered livers as described.(20)”
The Role of Chemokine Receptors in Renal Fibrosis
Wu, F., Sun, C. C., & Jianquan, L. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_21 · Cited by 23
Depletion of Bone Marrow-Derived Fibrocytes Attenuates TAA-Induced Liver Fibrosis in Mice
Hempel, F., Roderfeld, M., Savai, R., Sydykov, A. S., Irungbam, K., SCHERMULY, R. T., Voswinckel, R., Köhler, K., Churin, Y., Kiss, L., et al. (2019) · Cells · doi:10.3390/cells8101210 · Cited by 20
“Bone marrow transplantation, for instance, proved beneficial in murine cholestatic fibrosis but remains controversial as a treatment option for chronic liver diseases [48]; Cenicriviroc (CVC), a dual CCR2/CCR5-inhibitor impeding the infiltration of monocytes, is a promising drug candidate for NAFLD patients with fibro…”
BackgroundAdvances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
Sayıner, M., Lam, B. P., Golabi, P., & Younossi, Z. M. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818811508 · Cited by 20
Nonalcoholic Fatty Liver Disease
Ding, L., Oligschlaeger, Y., Shiri‐Sverdlov, R., & Houben, T. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_352 · Cited by 30
Feng, D. (2020) · Liver Research · doi:10.1016/j.livres.2020.02.003 · Cited by 18
HIV and liver disease: a comprehensive update.
Sherman, K. E., & Thomas, D. L. (2022) · PubMed · Cited by 23
New therapies target the toxic consequences of cholestatic liver disease
Jansen, P. L. M. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1424538 · Cited by 19
“UDCA 24-norUDCA Tauro-UDCA TGR5 agonists Decrease bile viscosity, increase bile salt transport and bicarbonate production Urso Falk, Ursochol NorUrso Falk TUDCA [45] INT 777 [10]; INT 767[43] Approved for PBC,PSC (in Europe) PSC, 01755507 [46] PBC, 01829698, 01857284 Not yet in trial FXR agonists FGF19 analogues Reduc…”
BackgroundReversal of NASH fibrosis with pharmacotherapy
Alukal, J. J., & Thuluvath, P. J. (2019) · Hepatology International · doi:10.1007/s12072-019-09970-3 · Cited by 17
Current and Emerging Approaches for Hepatic Fibrosis Treatment
Li, J., & Tuo, B. (2021) · Gastroenterology Research and Practice · doi:10.1155/2021/6612892 · Cited by 23
“Lefebvre and coworkers found that cenicriviroc has dramatic positive effects on anti-inflammation and antifibrosis in animal fibrosis models [75].”
BackgroundFrancque, S., Hodge, A. D., Boursier, J., Younes, Z. H., Rodriguez‐Araujo, G., Park, G. S., Alkhouri, N., & Abdelmalek, M. F. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000335 · Cited by 19
The PD-1/PD-L1 Axis in the Biology of MASLD
Pipitone, R. M., Lupo, G., Zito, R., Javed, A., Petta, S., Pennisi, G., & Grimaudo, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073671 · Cited by 22
“The chemokine (C-C motif) ligand (CCL) 2/C-C chemokine receptor 5 (CCR5) acts as a regulator of migration, activation, and proliferation of collagen-producing activated HSCs/myofibroblasts [132].”
Metadata
- Authors
- Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., Richards, T., Yoneyama, H., Jenkins, H., Wolfgang, G., & Friedman, S. L.
- Affiliations
- Chelsea and Westminster Hospital (GB)
- Columbia University Irving Medical Center (US)
- University of Pennsylvania (US)
- AIDS Research Consortium of Atlanta (US)
- Icahn School of Medicine at Mount Sinai (US)
- Stelic (Japan) (JP)
- Charles River Laboratories (Canada) (CA)
- Corresponding author
- Friedman, Scott L.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-06-27
- Volume
- 11
- Issue
- 6
- Pages
- e0158156
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4922569
- OpenAlex
- W2467384826
- Cited by
- 323
- References
- 51
- Citations by year
- 2026: 17 · 2025: 20 · 2024: 23 · 2023: 28 · 2022: 33 · 2021: 40 · 2020: 46 · 2019: 30 · 2018: 50 · 2017: 28 · 2016: 8
- FWCI
- 27.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute of General Medical Sciences (T32GM007170)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- cenicriviroc, antifibrotic effect, liver fibrosis, renal fibrosis, nonalcoholic steatohepatitis, monocyte/macrophage recruitment, MCP-1, RANTES, hepatic stellate cell activation, collagen deposition, chemokine signaling, thioacetamide-induced liver fibrosis, diet-induced NASH
- MeSH terms
- Animals, Chemotaxis, Fibrosis, Imidazoles, Kidney Diseases, Macrophages, Male, Mice, Inbred C57BL, Monocytes, Sulfoxides, Rats, Sprague-Dawley, Mice, Rats, Receptors, CCR2, CCR5 Receptor Antagonists, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.